NeOnc Technologies and the Department of Health – Abu Dhabi Sign MoU to Advance Brain Cancer Research and Proposed Clinical Collaboration
Two children are receiving investigational NEO100 in Abu Dhabi as NeOnc works to open a Phase 1 study there.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (Nasdaq: NTHI) signed a non-binding memorandum of understanding with the Department of Health – Abu Dhabi for CNS oncology collaboration. The two-year framework covers scientific exchange, specialist training and real-world evidence, with proposed clinical research and a potential regional presence.
Two children in Abu Dhabi are receiving investigational NEO100 through compassionate care; NeOnc expects a third child from India this week. The company is working to open a Phase 1 NEO100 study in the Emirate. June 2026 research clearances covered NEO100 and NEO212, but UAE enrollment requires additional conditions, including separate institutional review board approval. Pediatric NEO100 studies remain subject to further protocol review. Clinical collaboration and potential manufacturing, supply or distribution activities require separate agreements and applicable approvals.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointSigned MoU with the Department of Health – Abu Dhabi establishes a framework for CNS oncology collaboration.
- Moderate point. Forward-looking: it has not happened yet and may not happen.NeOnc is working to open a Phase 1 NEO100 study in Abu Dhabi.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed scientific exchange, specialist training and real-world evidence collaboration support clinical research capability.
- Minor point. Forward-looking: it has not happened yet and may not happen.Two children in Abu Dhabi receive compassionate-care NEO100; a third from India is expected this week.
- Minor pointJune 2026 DoH research clearances covered NEO100 and NEO212.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential regional presence and manufacturing, supply or distribution activities will be explored in Abu Dhabi.
Negative
- Moderate pointMoU is non-binding and does not restrict either party from similar arrangements with other institutions.
- Moderate pointClinical research collaboration requires a separate agreement and applicable regulatory approvals.
- Minor pointUAE patient enrollment requires additional conditions, including separate DoH institutional review board approval.
- Minor pointPediatric NEO100 Phase 1 and Phase 1b studies remain pending further protocol review.
- Minor pointPotential regional operations remain subject to further assessment, approvals and necessary definitive agreements.
Key Figures
- MoU term
- 2 years
- Effective upon signature, unless terminated earlier
- Termination notice
- At least 3 months
- Notice of a party's wish to terminate the MoU
- Children receiving NEO100
- 2 children
- Currently receiving investigational NEO100 through the Compassionate Care program in Abu Dhabi
Historical Context
-
Reported early clinical improvement in the first Abu Dhabi child receiving NEO100 through compassionate care.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
memorandum of understanding regulatory
investigational new drug regulatory
institutional review board regulatory
real-world evidence medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Proposed collaboration covers scientific exchange, specialist training and real-world evidence, alongside assessment of clinical trial opportunities and a potential regional presence for NeOnc in Abu Dhabi
Two children in Abu Dhabi are receiving investigational NEO100 through NeOnc’s Compassionate Care program, with a third expected this week
CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today announced that it has signed a Memorandum of Understanding (MoU) with the Department of Health – Abu Dhabi (DoH) to cooperate on the development of research and clinical capability in oncology and central nervous system therapeutics in the Emirate of Abu Dhabi. The MoU was signed on the sidelines of the Abu Dhabi Future Health Summit (ADFHS) 2026.
Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc Technologies Holdings, Inc., said: “For families facing brain cancer, access to investigational treatments and clinical research opportunities matters deeply. This proposed collaboration creates a framework to bring NeOnc’s development expertise together with Abu Dhabi’s clinical capabilities, with the goal of advancing research and expanding opportunities for patients closer to home. We are grateful to the Department of Health – Abu Dhabi for its commitment to addressing the needs of patients with complex and rare CNS cancers, including children.”
H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi (DoH), said: “For patients and families facing complex CNS cancers, every advance in research offers hope for more effective care and better quality of life. Our proposed collaboration with NeOnc connects international expertise with Abu Dhabi’s clinical capabilities to strengthen the evidence and skills needed to evaluate new approaches responsibly. By developing specialist knowledge and a deeper understanding of these critical conditions, we aim to support care that responds more closely to each patient’s needs, reflecting our commitment to bringing scientific advances closer to our community and beyond.”
The MoU builds on NeOnc’s existing activity in the Emirate, where DoH is the government entity responsible for regulating the health sector. In June 2026, DoH granted Investigational New Drug (IND) status for NEO100, covering the Company’s NEO100-01, NEO100-02 and NEO100-03 protocols across Phase 1, Phase 1b and Phase 2 studies in adults with progressive or recurrent Grade III or IV gliomas, together with pediatric studies authorized for Phase 1 and Phase 1b pending further protocol review. That authorization followed DoH’s IND clearance for NEO212, also announced in June 2026. The DoH clearances apply to the conduct of clinical research and do not constitute marketing authorization, and NeOnc must satisfy additional conditions, including separate DoH Institutional Review Board approval, before patient enrollment in the UAE. Two children in Abu Dhabi are currently receiving investigational NEO100 through NeOnc’s Compassionate Care program. A third child is expected to be onboarded from India this week. Building on that experience and on the Company’s existing DoH clearances, NeOnc is working to open a Phase 1 study of NEO100 in the Emirate.
Under the MoU, the parties will exchange scientific and clinical knowledge and expertise in CNS oncology and in the development and translation of therapeutics for rare, pediatric and high-unmet-need conditions; exchange expertise on clinical development methodologies, including trial design, endpoint selection and response assessment criteria, in support of strengthening clinical development capability in the Emirate; and cooperate on the generation and exchange of real-world evidence and clinical insights relating to CNS tumors in Abu Dhabi, including epidemiological and outcomes data, in accordance with applicable data protection legislation and subject to the required approvals.
The parties will also collaborate on training, capacity-building and professional development initiatives for investigators, clinical research coordinators and allied healthcare professionals, including in clinical trial conduct, neuro-oncology imaging assessment methodologies and molecular diagnostics relevant to CNS tumors, and on the development of Abu Dhabi’s life sciences ecosystem.
The MoU further provides for cooperation on the advancement of clinical research in CNS oncology, including studies of NeOnc’s investigational programs, subject to a separate agreement between the parties and to all applicable regulatory requirements and approvals. Subject to a separate agreement and to all applicable laws, regulations and approvals, the parties will also explore the potential establishment of a regional presence and manufacturing, supply or distribution activities by NeOnc in the Emirate, and the positioning of Abu Dhabi as a potential regional platform for NeOnc’s future development activities. These potential activities remain subject to further assessment, applicable approvals and any necessary definitive agreements.
The MoU is not a binding contract on either party. It takes effect upon signature by representatives of both parties and remains in effect for two years, unless either party gives at least three months’ notice of its wish to terminate. The MoU does not restrict either party from entering into similar arrangements with other institutions.
About the Department of Health – Abu Dhabi (DoH)
The Department of Health – Abu Dhabi is the regulator of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritizes health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programs in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH’s unwavering commitment to predicting, preventing and personalizing healthcare for every individual.
For further information on DoH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the Company’s proposed collaboration with the Department of Health – Abu Dhabi, the Company’s clinical development activities in the United Arab Emirates, and the potential establishment of a regional presence in the Emirate. These statements reflect current expectations and involve risks and uncertainties. The Memorandum of Understanding is not binding and may not result in any definitive agreement; activities contemplated by the parties remain subject to separate agreement and to applicable regulatory, institutional and other approvals; future studies may not demonstrate safety or efficacy; and no regulatory pathway or marketing approval is assured. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release.
The Company undertakes no obligation to update forward-looking statements except as required by law.
“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Contacts
| DoH Media Contact: Mariam Al Marzooqi msalmarzooqi@doh.gov.ae +971 50 536 6660 | NeOnc Company Contact: info@neonc.com NeOnc Investor Contact: Jon Nugent Jon Nugent Communications jon@jonnugent.com 205-566-3026 |
This press release was published by a CLEAR® Verified individual.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does NeOnc's Abu Dhabi MoU cover?
The non-binding MoU covers scientific and clinical knowledge exchange, specialist training and real-world evidence in CNS oncology. It also provides a framework for proposed clinical research and exploration of a potential regional presence, including manufacturing, supply or distribution activities, subject to separate agreements and applicable approvals.
How long does NeOnc's Abu Dhabi MoU last, and can either party terminate it?
The MoU takes effect upon signature by both parties and lasts two years, unless either party gives at least three months’ notice of its wish to terminate. Neither party is restricted from entering into similar arrangements with other institutions.
Which adult NEO100 studies received Abu Dhabi research clearance?
The June 2026 NEO100 authorization covered NEO100-01, NEO100-02 and NEO100-03 across Phase 1, Phase 1b and Phase 2 studies in adults with progressive or recurrent Grade III or IV gliomas. These are research clearances, not marketing authorization.
What conditions apply to real-world evidence sharing under NeOnc's Abu Dhabi MoU?
Generation and exchange of real-world evidence must comply with applicable data protection legislation and receive required approvals. The proposed cooperation includes epidemiological and outcomes data relating to CNS tumors in Abu Dhabi.